CFDE Data Portal | Search AGAP2-AS1

	Label	Description
	AGAP2-AS1 associations Collection (Entity type)	Associations for AGAP2-AS1_associations
	AGAP2-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	AGAP2-AS1 Gene (Entity type)	ENSG00000255737 - AGAP2 antisense RNA 1
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 3 V 2 VALPROIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

AGAP2-AS1 associations

Associations for AGAP2-AS1_associations

AGAP2-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

AGAP2-AS1

ENSG00000255737 - AGAP2 antisense RNA 1

GSE240439 decitabine 1 v 2 human up

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE195663 cisplatin 0 v 1 human up

A Gene Set from LINCS

GSE187006 3 V 2 VALPROIC ACID HUMAN UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.